Nichi-Iko Pharmaceutical is off to a new start making the former Elmed Eisai its wholly owned subsidiary on April 1.…
REGULATORY
ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
The health ministry’s Central Social Insurance Medical Council (Chuikyo) on December 5 approved the expedited NHI price listing of ViiV Healthcare’s dual HIV therapy Juluca (dolutegravir + rilpivirine). The drug will be listed on December 12. The drug, which received…
To read the full story
Related Article
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
REGULATORY
- MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
- Lilly’s EGFR Antagonist, Japan’s 1st Avastin Biosimilar Now in Line for June Approval
April 22, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- Japan Drug Production Up 1.5% to 6.7 Trillion Yen in 2017: MHLW Survey
April 18, 2019
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now -…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…